These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 28606127)
21. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308 [TBL] [Abstract][Full Text] [Related]
22. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564 [TBL] [Abstract][Full Text] [Related]
23. CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma. Wang Z; Yin F; Xu J; Zhang T; Wang G; Mao M; Wang Z; Sun W; Han J; Yang M; Jiang Y; Hua Y; Cai Z J Exp Clin Cancer Res; 2019 Jan; 38(1):44. PubMed ID: 30704503 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. El Sayed I; Helmy MW; El-Abhar HS Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831 [TBL] [Abstract][Full Text] [Related]
25. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301 [TBL] [Abstract][Full Text] [Related]
26. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945 [TBL] [Abstract][Full Text] [Related]
27. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo. Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561 [TBL] [Abstract][Full Text] [Related]
28. The role of Src in prostate cancer. Fizazi K Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060 [TBL] [Abstract][Full Text] [Related]
29. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709 [TBL] [Abstract][Full Text] [Related]
30. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564 [TBL] [Abstract][Full Text] [Related]
31. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004 [TBL] [Abstract][Full Text] [Related]
32. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106 [TBL] [Abstract][Full Text] [Related]
33. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659 [TBL] [Abstract][Full Text] [Related]
34. Src controls castration recurrence of CWR22 prostate cancer xenografts. Su B; Gillard B; Gao L; Eng KH; Gelman IH Cancer Med; 2013 Dec; 2(6):784-92. PubMed ID: 24403252 [TBL] [Abstract][Full Text] [Related]
35. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. Thibault B; Jean-Claude B J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239 [TBL] [Abstract][Full Text] [Related]
36. [FAK/c-Src signaling pathway mediates the expression of cell surface HSP90 in cultured human prostate cancer cells and its association with their invasive capability]. Liu XG; Guo Y; Yan ZQ; Guo MY; Zhang ZG; Guo CA Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):340-4. PubMed ID: 21875461 [TBL] [Abstract][Full Text] [Related]